CATH Search:   
       by CATH code, keyword
QuickSearch:   
by PDB,NDB,UniProt,PROSITE Code or Search Term(s)  
(use 'Shift Left-Click' to collapse/expand all levels downwards; use 'Control Left-Click' to collapse/expand all levels upwards)
 
(-)
Class: Mainly Alpha (13335)
(-)
Architecture: Orthogonal Bundle (10391)
(-)
Topology: Serum Albumin; Chain A, Domain 1 (74)
(-)
Homologous Superfamily: [code=1.10.246.10, no name defined] (60)
(-)
Human (Homo sapiens) (57)
1AO6A:205-296; A:297-382; B:297-382; B:205-296; A:5-107; B:5-107; A:495-572; B:495-572; A:383-494; B:383-494; A:108-197; B:108-197CRYSTAL STRUCTURE OF HUMAN SERUM ALBUMIN
1BJ5A:205-296; A:297-382; A:5-107; A:495-569; A:383-494; A:108-197HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTIC ACID
1BKEA:205-296; A:108-197; A:297-382; A:5-107; A:495-574; A:383-494HUMAN SERUM ALBUMIN IN A COMPLEX WITH MYRISTIC ACID AND TRI-IODOBENZOIC ACID
1BM0A:205-296; A:297-382; B:297-382; A:5-107; B:205-296; B:5-107; A:495-572; B:495-572; A:383-494; B:383-494; A:108-197; B:108-197CRYSTAL STRUCTURE OF HUMAN SERUM ALBUMIN
1E78A:205-296; A:108-197; B:108-197; A:297-382; B:297-382; A:5-107; B:5-107; A:495-572; B:495-572; B:205-296; A:383-494; B:383-494CRYSTAL STRUCTURE OF HUMAN SERUM ALBUMIN
1E7AA:205-296; A:297-382; B:297-382; A:5-107; B:5-107; A:495-572; B:495-572; A:383-494; B:383-494; B:205-296; A:108-197; B:108-197CRYSTAL STRUCTURE OF HUMAN SERUM ALBUMIN COMPLEXED WITH THE GENERAL ANESTHETIC PROPOFOL
1E7BA:205-296; B:205-296; B:297-382; A:298-382; A:5-107; B:5-107; A:495-572; B:495-572; A:383-494; B:383-494; A:108-197; B:108-197CRYSTAL STRUCTURE OF HUMAN SERUM ALBUMIN COMPLEXED WITH THE GENERAL ANESTHETIC HALOTHANE
1E7CA:205-296; A:297-382; A:5-107; A:495-574; A:383-494; A:108-197HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTIC ACID AND THE GENERAL ANESTHETIC HALOTHANE
1E7EA:205-296; A:297-382; A:5-107; A:495-577; A:383-494; A:108-197HUMAN SERUM ALBUMIN COMPLEXED WITH DECANOIC ACID (CAPRIC ACID)
1E7FA:205-296; A:297-382; A:5-107; A:495-572; A:383-494; A:108-197HUMAN SERUM ALBUMIN COMPLEXED WITH DODECANOIC ACID (LAURIC ACID)
1E7GA:205-296; A:297-382; A:5-107; A:495-574; A:383-494; A:108-197HUMAN SERUM ALBUMIN COMPLEXED WITH TETRADECANOIC ACID (MYRISTIC ACID)
1E7HA:205-296; A:297-382; A:5-107; A:495-566; A:383-494; A:108-197HUMAN SERUM ALBUMIN COMPLEXED WITH HEXADECANOIC ACID (PALMITIC ACID)
1E7IA:205-296; A:108-197; A:297-382; A:5-107; A:495-569; A:383-494HUMAN SERUM ALBUMIN COMPLEXED WITH OCTADECANOIC ACID (STEARIC ACID)
1GNIA:205-296; A:297-382; A:5-107; A:495-573; A:383-494; A:108-197HUMAN SERUM ALBUMIN COMPLEXED WITH CIS-9-OCTADECENOIC ACID (OLEIC ACID)
1GNJA:205-296; A:108-197; A:297-382; A:5-107; A:495-570; A:383-494HUMAN SERUM ALBUMIN COMPLEXED WITH CIS-5,8,11,14-EICOSATETRAENOIC ACID (ARACHIDONIC ACID)
1H9ZA:205-296; A:108-197; A:297-382; A:5-107; A:495-570; A:383-494HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTIC ACID AND THE R-(+) ENANTIOMER OF WARFARIN
1HA2A:205-296; A:108-197; A:297-382; A:5-107; A:495-573; A:383-494HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTIC ACID AND THE S-(-) ENANTIOMER OF WARFARIN
1HK1A:205-296; A:108-197; A:297-382; A:5-107; A:495-568; A:383-494HUMAN SERUM ALBUMIN COMPLEXED WITH THYROXINE (3,3',5,5'-TETRAIODO-L-THYRONINE)
1HK2A:205-296; A:108-197; A:297-382; A:5-107; A:495-572; A:383-494HUMAN SERUM ALBUMIN MUTANT R218H COMPLEXED WITH THYROXINE (3,3',5,5'-TETRAIODO-L-THYRONINE)
1HK3A:205-296; A:108-197; A:297-382; A:5-107; A:495-572; A:383-494HUMAN SERUM ALBUMIN MUTANT R218P COMPLEXED WITH THYROXINE (3,3',5,5'-TETRAIODO-L-THYRONINE)
1HK4A:205-296; A:297-382; A:5-107; A:495-570; A:383-494; A:108-197HUMAN SERUM ALBUMIN COMPLEXED WITH THYROXINE (3,3',5,5'-TETRAIODO-L-THYRONINE) AND MYRISTIC ACID (TETRADECANOIC ACID)
1HK5A:205-296; A:108-197; A:297-382; A:5-107; A:495-572; A:383-494HUMAN SERUM ALBUMIN MUTANT R218H COMPLEXED WITH THYROXINE (3,3',5,5'-TETRAIODO-L-THYRONINE) AND MYRISTIC ACID (TETRADECANOIC ACID)
1J78A:124-211; B:124-211; A:212-299; B:212-299; A:13-111; B:7-111; A:315-391; B:315-391; A:398-457; B:398-456CRYSTALLOGRAPHIC ANALYSIS OF THE HUMAN VITAMIN D BINDING PROTEIN
1J7EA:124-211; B:124-211; A:212-299; B:212-299; A:7-111; B:7-111; A:315-391; B:315-391; A:398-457; B:398-456A STRUCTURAL BASIS FOR THE UNIQUE BINDING FEATURES OF THE HUMAN VITAMIN D-BINDING PROTEIN
1KW2A:140-227; B:140-227; A:228-315; B:228-315; A:23-127; B:23-127; A:331-407; B:331-407; A:414-473; B:414-473CRYSTAL STRUCTURE OF UNCOMPLEXED VITAMIN D-BINDING PROTEIN
1LOTA:124-211; A:212-299; A:7-112; A:315-391; A:398-457CRYSTAL STRUCTURE OF THE COMPLEX OF ACTIN WITH VITAMIN D-BINDING PROTEIN
1MA9A:124-211; A:212-299; A:3-111; A:315-391; A:398-457CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN VITAMIN D BINDING PROTEIN AND RABBIT MUSCLE ACTIN
1N5UA:205-296; A:297-382; A:5-107; A:495-569; A:383-494; A:108-197X-RAY STUDY OF HUMAN SERUM ALBUMIN COMPLEXED WITH HEME
1O9XA:205-296; A:108-197; A:297-382; A:5-107; A:495-574; A:383-494HUMAN SERUM ALBUMIN COMPLEXED WITH TETRADECANOIC ACID (MYRISTIC ACID) AND HEMIN
1TF0A:205-296; A:108-197; A:297-382; A:5-107; A:495-568; A:383-494CRYSTAL STRUCTURE OF THE GA MODULE COMPLEXED WITH HUMAN SERUM ALBUMIN
1UORA:205-297; A:109-197; A:299-382; A:4-107; A:495-575; A:383-494X-RAY STUDY OF RECOMBINANT HUMAN SERUM ALBUMIN. PHASES DETERMINED BY MOLECULAR REPLACEMENT METHOD, USING LOW RESOLUTION STRUCTURE MODEL OF TETRAGONAL FORM OF HUMAN SERUM ALBUMIN
2BX8A:205-296; A:108-197; B:108-197; A:297-382; B:297-382; A:5-107; B:5-107; A:495-572; B:495-572; A:383-494; B:383-494; B:205-296HUMAN SERUM ALBUMIN COMPLEXED WITH AZAPROPAZONE
2BXAA:205-296; B:205-296; A:297-382; B:297-382; B:5-107; A:5-107; A:495-572; B:495-572; A:383-494; B:383-494; A:108-197; B:108-197HUMAN SERUM ALBUMIN COMPLEXED WITH 3-CARBOXY-4-METHYL-5-PROPYL-2-FURANPROPANOIC ACID (CMPF)
2BXBA:205-296; A:108-197; B:108-197; A:297-382; B:297-382; A:5-107; B:5-107; A:495-572; B:495-572; A:383-494; B:383-494; B:205-296HUMAN SERUM ALBUMIN COMPLEXED WITH OXYPHENBUTAZONE
2BXCA:205-296; A:108-197; B:108-197; A:297-382; B:297-382; A:5-107; B:5-107; A:495-572; B:495-572; A:383-494; B:383-494; B:205-296HUMAN SERUM ALBUMIN COMPLEXED WITH PHENYLBUTAZONE
2BXDA:205-296; A:108-197; B:108-197; A:297-382; B:297-382; A:5-107; B:5-107; A:495-572; B:495-572; A:383-494; B:383-494; B:205-296HUMAN SERUM ALBUMIN COMPLEXED WITH WARFARIN
2BXEA:205-296; A:108-197; B:108-197; A:297-382; B:297-382; B:5-107; A:5-107; A:495-572; B:495-572; A:383-494; B:383-494; B:205-296HUMAN SERUM ALBUMIN COMPLEXED WITH DIFLUNISAL
2BXFA:205-296; A:108-197; B:108-197; A:297-382; B:297-382; A:5-107; B:5-107; A:495-572; B:495-572; A:383-494; B:383-494; B:205-296HUMAN SERUM ALBUMIN COMPLEXED WITH DIAZEPAM
2BXGA:205-296; A:108-197; B:108-197; A:297-382; B:297-382; A:5-107; B:5-107; A:495-572; B:495-572; A:383-494; B:383-494; B:205-296HUMAN SERUM ALBUMIN COMPLEXED WITH IBUPROFEN
2BXHA:205-296; A:297-382; B:297-382; A:5-107; B:5-107; A:383-494; B:383-494; A:495-561; B:495-561; B:205-296; A:108-197; B:108-197HUMAN SERUM ALBUMIN COMPLEXED WITH INDOXYL SULFATE
2BXIA:205-296; A:108-197; A:297-382; A:3-107; A:495-569; A:383-494HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTATE AND AZAPROPAZONE
2BXKA:205-296; A:297-382; A:3-107; A:495-569; A:383-494; A:108-197HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTATE, AZAPROPAZONE AND INDOMETHACIN
2BXLA:205-296; A:108-197; A:297-382; A:3-107; A:495-569; A:383-494HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTATE AND 3,5-DIIODOSALICYLIC ACID
2BXMA:205-296; A:108-197; A:297-382; A:3-107; A:495-568; A:383-494HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTATE AND INDOMETHACIN
2BXNA:205-296; A:108-197; A:297-382; A:5-107; A:495-569; A:383-494HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTATE AND IODIPAMIDE
2BXOA:205-296; A:108-197; A:297-382; A:3-107; A:495-578; A:383-494HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTATE AND OXYPHENBUTAZONE
2BXPA:205-296; A:297-382; A:3-107; A:495-568; A:383-494; A:108-197HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTATE AND PHENYLBUTAZONE
2BXQA:205-296; A:108-197; A:297-382; A:3-107; A:495-569; A:383-494HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTATE, PHENYLBUTAZONE AND INDOMETHACIN
2I2ZA:205-296; A:108-197; A:297-382; A:3-107; A:495-572; A:383-494HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTATE AND ASPIRIN
2I30A:205-296; A:108-197; A:297-382; A:3-107; A:495-572; A:383-494HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTATE AND SALICYLIC ACID
2VDBA:205-296; A:108-197; A:297-382; A:6-107; A:495-574; A:383-494STRUCTURE OF HUMAN SERUM ALBUMIN WITH S-NAPROXEN AND THE GA MODULE
2VUEA:205-296; A:297-382; B:297-382; B:205-296; B:5-107; A:5-107; A:495-572; B:495-572; A:383-494; B:383-494; A:108-197; B:108-197HUMAN SERUM ALBUMIN COMPLEXED WITH 4Z,15E-BILIRUBIN-IX-ALPHA
2VUFA:205-296; A:108-197; B:108-197; A:297-382; B:297-382; A:5-107; B:5-107; A:495-568; B:495-562; A:383-494; B:383-494; B:205-296HUMAN SERUM ALBUMIN COMPLEXED WITH FUSIDIC ACID
3A73A:205-296; A:297-382; B:297-382; B:205-296; A:2-107; B:2-107; B:495-573; A:495-569; A:383-494; B:383-494; A:108-197; B:108-197CRYSTAL STRUCTURE ANALYSIS OF HUMAN SERUM ALBUMIN COMPLEXED WITH DELTA 12-PROSTAGLANDIN J2
3CX9A:205-296; A:108-197; A:297-382; A:5-107; A:495-574; A:383-494CRYSTAL STRUCTURE OF HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTIC ACID AND LYSOPHOSPHATIDYLETHANOLAMINE
3JQZA:205-296; A:108-197; B:108-197; A:297-382; B:297-382; A:1-107; B:1-107; B:495-572; A:495-568; A:383-494; B:383-494; B:205-296CRYSTAL STRUCTURE OF HUMAN SERUM ALBUMIN COMPLEXED WITH LIDOCAINE
3JRYA:205-296; A:297-382; B:297-382; A:5-107; B:5-107; A:495-568; B:495-568; A:383-494; B:383-494; A:108-197; B:108-197; B:205-296HUMAN SERUM ALBUMIN WITH BOUND SULFATE